Gastro Pharma with momentum
This morning I added Sucampo Pharmaceuticals (SCMP) to the Barchart Van Meerten Speculative portfolio.
Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.
The 16 new highs and price appreciation in the last month has earned the stock a 100% Barchart technical buy signal. The stock recently traded around 4.55 with a 50 day moving average and a Relative Strength Index of 85.95% which is still on the rise.
The lone Wall Street brokerage analyst following the stock has a strong Buy recommendation publishedbased on his projection that sales will increase by 10.80% next year and earnings will increase 11.00% per year for at least 5 years.
The CAPS members on Motley Fool have voted 61 to 11 that the stock will beat the market with the All Stars in agreement 25 to 2. Fool notes that there have been 3 recent articles that have all been positive.
Jim Van Meerten is a professional investor with over 40 year experience in investing in stocks, mutual funds and ETFs. He shares his knowledge on Barchart in his daily blogs -- Barchart Portfolio Blogs.
Through Marketocracy Capital Management you can have a Separately Managed Account that mirrors his Barchart Van Meerten New High portfolio.